To meet weight loss drug demand, Eli Lilly today has begun selling vials of the smallest, starter dose of its popular weight-loss drug Zepbound in the U.S. at about half the price – $399 – for a month's supply. That's a 50% discount compared to the list price of $1,000 a month for other GLP-1 obesity medicines.
Lilly is selling the smaller vials on its direct-to-consumer website, LillyDirect, to try to increase supplies in the marketplace, since many patients have health insurance that will not cover weight loss medications.
Zepbound is typically packaged in an auto-injector pen that contains both the drug and the needle. With the new vials, patients will be able to use a syringe to draw out their dose and then inject themselves. The vials will provide a more affordable option because it saves production time to make than injection pens, according to Lilly.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
